Barry R. Edwards has been Chief Executive Officer since January 1, 2004, a Director since January 1999 and was Co-Chief Executive Officer of the Company since December 14, 1999. From August 1998 until January 1999, Mr. Edwards served as President of the Company and from January 1999 until December 1999, Mr. Edwards served as Chief Executive Officer of the Company. From 1996 to 1998, Mr. Edwards was Vice President, Marketing and Business Development for Teva Pharmaceuticals USA, one of the largest generic drug companies. From 1991 to 1996, Mr. Edwards served as Executive Director of Gate Pharmaceuticals, a brand marketing division of Teva Pharmaceuticals USA. Prior to 1991, Mr. Edwards held a number of management functions in strategic planning, corporate development, business development and marketing at Teva Pharmaceuticals USA.

William A. Fletcher has served as Group Vice President - North America since April 2002 and as President and Chief Executive Officer of Teva North America since April 2000. He previously served as President and Chief Executive Officer of Teva USA from 1983 through March 2000. Mr. Fletcher has also served as Vice President-North American Pharmaceutical Sales since 1995. Prior to joining Teva USA, he was Business Development Manager and International Marketing Manager of Synthelabo, a subsidiary of L'Oreal in Paris. He graduated in International Marketing from Woolwich Polytechnic, London (now Greenwich University) in 1969.

Dr. Gavin is a founding partner of Quaker BioVentures. Previously, she was President of S.R. One, Limited (S.R. One), GlaxoSmithKline PLC's (GSK) bioscience venture capital investment company, and a general partner of EuclidSR Partners, an independent venture capital limited partnership focused on healthcare, information technology, and their convergence. Since its inception in 1985, S.R. One has invested over $340 million in approximately 100 life sciences companies and 20 venture funds. Dr. Gavin was responsible for many of the direct venture and strategic investments made by S.R. One. She served as a board member or active board observer for many of these, including Adolor, Amgen, Inhale, Sepracor and Versicor.

Prior to joining S.R. One in 1989, Dr. Gavin was Director of Business Development for SmithKline Beecham Animal Health Products. She started her career as an epidemiologist at the Centers for Disease Control and Prevention.

Dr. Gavin is a graduate of Baylor University where she majored in Biology. She received her Doctor of Veterinary Medicine from the University of Missouri and her Master of Business Administration from the University of Texas - San Antonio. Dr. Gavin is highly regarded in the venture capital community and is a board member of the National Venture Capital Association, the Ben Franklin Technology Center of Southeastern Pennsylvania, the Ben Franklin Technology Development Authority, Innovation Philadelphia, BioAdvance (the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania), and serves on the advisory boards of the Pennsylvania State University Research Foundation and the Monell Institute.

Elaine V. Jones has a background in basic research and product assessment built on her significant experience in pharmaceutical discovery and business development. Prior to joining EuclidSR Partners, Elaine began her private equity career in 1999 at S.R. One, Limited, SmithKline Beecham's venture investing arm. Previously, she was a Director of Scientific Licensing for SmithKline Beecham, where she identified and assessed therapeutic product opportunities in arthritis, bone disease, urology and cancer. Elaine is a graduate of Juniata College and received her Ph.D. from the University of Pittsburgh.

Daniel R. Omstead, Eng.ScD, is President and Chief Executive Officer of Hambrecht & Quist Capital Management, Inc. He is also President of H&Q Lifesciences Investors and H&Q Healthcare Investors, two NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining HQCM, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.

Dr. Robert J. Rubin is currently Clinical Professor of Medicine in the Division of Nephrology and Hypertension at the Georgetown University School of Medicine and an independent healthcare consultant. Prior to becoming an independent consultant, Dr. Rubin was president of The Lewin Group, an international health care consultancy, for 17 years. During that time, Dr. Rubin served as Medical Director for a pharmaceutical benefit management company (1992-1996) and Chair of the Board of a biotech start-up.

From 1981-1984, Dr. Rubin was the Assistant Secretary for Planning and Evaluation at the US Department of Health and Human Services (HHS) under President Reagan. In that capacity he was the chair of the task forces charged with the design, passage and implementation of Medicare's Prospective Payment System as well as the primary policy advisor to the HHS secretary.

As a healthcare consultant, Dr. Rubin worked extensively with pharmaceutical, medical device and biotech companies to develop strategic and marketing plans for new devices and drugs. He also worked with many of the leading academic health centers in the US to help them develop strategic plans especially in the area of biomedical research. In addition, he has and continues to advise several government agencies on health care policy.

Dr. Rubin graduated from Williams College and received his M.D. from Cornell University Medical College. He served as an Epidemic Intelligence Service officer at the Centers for Disease Control from 1972-1974.

Dr. Jeffrey L. Sturchio is Vice President, External Affairs, Human Health--Europe, Middle East & Africa at Merck & Co., Inc., in Whitehouse Station, New Jersey. He is responsible for the development, coordination, and implementation of a range of health policy and communications initiatives for the region. He has been centrally involved in Merck's participation in the UN/industry Accelerating Access Initiative to help improve HIV/AIDS care and treatment in the developing world. He is also a member of the private sector delegation to the Board of the Global Fund to Fight AIDS, TB and Malaria.

Dr. Sturchio received an A.B. in history (1973) from Princeton University and a Ph.D. in the history & sociology of science from the University of Pennsylvania (1981). His previous positions include the AT&T Archives, the Beckman Center for the History of Chemistry at the University of Pennsylvania, Rutgers University, and the New Jersey Institute of Technology. He has also been a Postdoctoral Fellow and Senior Fellow at the Smithsonian Institution's National Museum of American History (NMAH). He joined Merck in June 1989 as the Company's first Corporate Archivist.

His publications include Chemistry in America, 1876-1976: Historical Indicators (Reidel, 1985; paperback edition, 1988), written with A. Thackray, P. T. Carroll, and R. F. Bud; Values & Visions: A Merck Century (Merck & Co., Inc., 1991); "Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation" (with L. Galambos), Business History Review 72 (Summer 1998): 250-278; "Against: Direct to consumer advertising is medicalising normal human experience" (with S. Bonaccorso), British Medical Journal 324 (13 April 2002): 910-911; and "Successful public-private partnerships in global health: lessons from the MECTIZAN Donation Program," (with B. Colatrella), in The Economics of Essential Medicines, ed. by B. Granville (London: Royal Institute of International Affairs, 2002).

Dr. Peter West joined York Health Economics Consortium, University of York, as Director in January 2000. Peter has a BA in Economics and DPhil in Health Economics from the University of York. Since completing his first degree, he has spent more than 25 years working on the economics of health care in academic teaching and research, management development, and consultancy. He has taught at several British universities including the London School of Economics, the University of Sussex, and the University of Bath, and was a fellow of the King's Fund College, a leading management development centre for the NHS. He also spent seven years in management consultancy with Deloitte and Touche in London.

Peter is the author of numerous journal articles, a doctoral dissertation on Resource Allocation to the regions of the English NHS, a standard textbook of health economics (with John Cullis), and a review of incentives in the NHS, published by the King's Fund. The Open University Press published his book on the economics of the NHS Reforms in the UK in the summer of 1997. He has also published a review of the future of hospitals for the Nuttfield Trust and an Assessment of the potential development of Managed Care in the NHS for the Office of Health Economics.

Peter West has carried out a wide range of consulting assignments for all levels of the NHS, for pharmaceutical companies, and for several government aid agencies. Recent consulting reports include a range of cost-effectiveness studies of new pharmaceuticals, several of which were submitted to NICE, and an assessment of the initiative to send NHS patients overseas. Peter has recently directed the analysis of the savings generated by parallel trade of medicines in Europe.